



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Patent Application of)
Isabelle NONOTTE et al.) Group Art Unit: 1616
Application No.: 10/665,372) Examiner:
Filed: September 22, 2003) Confirmation No.: 5014
For: MANGANESE COMPOSITIONS FOR)
TREATING SKIN VASCULAR TISSUE)
AND COMBATING SKIN PALLOR)

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ [X] No additional fee for submission of an IDS is required.
- ☐ [] The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ [] A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ [] A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ [] Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ [] A check in the amount of \$_____ is enclosed for the fee due.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: February 17, 2004

By: Mary Katherine Baumeister
Mary Katherine Baumeister
Registration No. 26,254

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620



Patent
Attorney's Docket No. 016800-643

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
Isabelle NONOTTE et al.)	Group Art Unit: 1616
Application No.: 10/665,372)	Examiner:
Filed: September 22, 2003)	Confirmation No.: 5014
For: MANGANESE COMPOSITIONS FOR)	
TREATING SKIN VASCULAR TISSUE)	
AND COMBATING SKIN PALLOR)	

SECOND
INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

In compliance with the requirements of 37 C.F.R. §§ 1.56, 197 and 1.98, applicants are filing herewith a Form PTO-1449 listing documents for the consideration of the Examiner. However, a copy of the listed U.S. patent is not enclosed since it is no longer required according to the July 11, 2003 waiver of the requirement for copies of cited U.S. patents and U.S. patent application publications in national patent applications filed after June 30, 2003 and international applications entering the national stage under 35 U.S.C. § 371 after June 30, 2003.

Breton et al. U.S. Patent No. 6,224, 850 B1 has been cited by the Examiner in copending Appln. No. 09/859,384, filed by the present inventors concurrently with their parent Appln. No. 09/859,392 on May 18, 2001. The Breton et al. '850 patent describes an extract of *Iridaceae* as a chlorine-channel receptor agonist for relaxing and/or loosening the cutaneous and/or subcutaneous tissue. Chlorine-channel openers may be present in the compositions administered in accord with the present invention.

The Narita et al. publication which is enclosed is a document whose abstract has been cited during prosecution of the European counterpart of Appln. No. 09/859,384.

Copending Application No. 09/859,384 has recently been abandoned in favor of a continuation Application No. 10/702,736 [Attorney Docket No. 016800-652], filed November 7, 2003. A copy of the continuation is provided herewith.

 In accordance with M.P.E.P. § 609(c)(2) (August 2001, page 600-131), the Office is requested to return a copy of this Information Disclosure Statement with the Examiner's initials adjacent to this paragraph indicating that this copending application has been considered. By citation to the copending application, confidentiality is not waived and the Office is requested to maintain the confidentiality of the copending application under 35 U.S.C. § 122.

This Information Disclosure Statement is being submitted within three (3) months of the filing or entry into the national stage of this application or before the first Office Action on the merits, whichever is later. Since this is being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

It is requested that the Examiner consider the documents cited by applicants and return an initialed copy of the accompanying Form PTO-1449 to the undersigned with the next official communication.


Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: February 17, 2004

By: Mary Katherine Baumeister
Mary Katherine Baumeister
Registration No. 26,254

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620



SHEET 1 OF 1

Substitute for forms 1449A/PTO & 1449B/PTO SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTORNEY'S DKT No. 016800-643	APPLICATION No. 10/665,372 (Continuation of 09/859,392)
	APPLICANT Isabelle NONOTTE et al.	
	FILING DATE September 22, 2003	GROUP 1616

U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	6,224,850	B1	Breton et al.	05-01-2001

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes No

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Narita et al, "Effects of Calcium Blockers and Mn ²⁺ on the Response of Isolated Rat Iris Sphincter and Dilator Muscles to Agonists and Ca ²⁺ ", <i>Journal of Pharmacobio-dynamics</i> , vol. 5, pp 285-294 (April, 1982) published by Pharmaceutical Society of Japan, Tokyo, Japan.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.